Northwestern Medicine Developmental Therapeutics Institute (NMDTI), Chicago, IL, USA; Division of Hematology and Oncology, Robert H. Lurie Medical Research Center, Room 5-121, 303 East Superior, Chicago, IL 60611, USA.
Division of Hematology and Oncology, Robert H. Lurie Medical Research Center, Room 5-121, 303 East Superior, Chicago, IL 60611, USA; Division of Hepatology and Gastroenterology, Northwestern University, 676 North St Clair, 19th Floor, Chicago, IL 60611, USA.
Clin Liver Dis. 2015 May;19(2):421-32. doi: 10.1016/j.cld.2015.01.009. Epub 2015 Mar 12.
Treatment of advanced hepatocellular carcinoma (HCC) remains challenging, particularly with the limited systemic therapy options. Sorafenib remains the only approved, targeted molecule for the treatment of advanced HCC. Although a survival benefit was demonstrated with sorafenib, it remains only true in the population of patients with Child-Turcotte-Pugh class A disease. Sorafenib also has distinct side effects that require close monitoring. Newer tyrosine kinase inhibitors and angiogenic inhibitors have been evaluated with disappointing results, particularly in phase III trials. Herein we review the pertinent trials for targeted therapy in HCC to date.
治疗晚期肝细胞癌 (HCC) 仍然具有挑战性，尤其是在系统治疗选择有限的情况下。索拉非尼仍然是唯一被批准用于治疗晚期 HCC 的靶向分子。尽管索拉非尼显示出了生存获益，但这仅适用于 Child-Turcotte-Pugh 分级为 A 级的患者群体。索拉非尼还具有明显的副作用，需要密切监测。新型酪氨酸激酶抑制剂和血管生成抑制剂的评估结果令人失望，尤其是在 III 期试验中。本文综述了迄今为止 HCC 靶向治疗的相关试验。
